Harnessing Growth Factors to Influence Wound Healing

Clinics in Plastic Surgery

Volumn 39, Issue 3, 2012, Pages 239-248

  Kiwanuka, Elizabeth ^a   Junker, Johan ^a   Eriksson, Elof ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Cytokines; Gene therapy; Growth factors; Wound healing

Indexed keywords

EPIDERMAL GROWTH FACTOR; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 10; FIBROBLAST GROWTH FACTOR 2; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 1; INTERLEUKIN 6; KERATINOCYTE GROWTH FACTOR; PLACEBO; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR B; RECOMBINANT PLATELET DERIVED GROWTH FACTOR; RECOMBINANT PLATELET DERIVED GROWTH FACTOR BB; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA2; TRANSFORMING GROWTH FACTOR BETA3; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN; VASCULOTROPIN A;

CHRONIC WOUND; DEBRIDEMENT; DECUBITUS; FOOT ULCER; HUMAN; LEG ULCER; LIMB ISCHEMIA; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SKIN INJURY; TREATMENT OUTCOME; ULCER; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; WOUND HEALING;

ANIMALS; CYTOKINES; DEBRIDEMENT; DIABETIC FOOT; FOOT ULCER; GENE THERAPY; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; INTERLEUKINS; PLATELET-DERIVED GROWTH FACTOR; RECOMBINANT PROTEINS; SKIN; WOUND HEALING; WOUNDS AND INJURIES;

EID: 84862727777     PISSN: 00941298     EISSN: 15580504     Source Type: Journal    
DOI: 10.1016/j.cps.2012.04.003     Document Type: Review

References (99)

1. Singer A.J., Clark R.A. Cutaneous wound healing. N Engl J Med 1999, 341:738-746.
2. Aarabi S., Longaker M.T., Gurtner G.C. Hypertrophic scar formation following burns and trauma: new approaches to treatment. PLoS Med 2007, 4:e234.
3. Gurtner G.C., Werner S., Barrandon Y., et al. Wound repair and regeneration. Nature 2008, 453:314-321.
4. Mustoe T. Understanding chronic wounds: a unifying hypothesis on their pathogenesis and implications for therapy. Am J Surg 2004, 187:65S-70S.
5. Grose R., Werner S. Wound-healing studies in transgenic and knockout mice. Mol Biotechnol 2004, 28:147-166.
6. Martin P., Leibovich S.J. Inflammatory cells during wound repair: the good, the bad and the ugly. Trends Cell Biol 2005, 15:599-607.
7. Werner S., Krieg T., Smola H. Keratinocyte-fibroblast interactions in wound healing. J Invest Dermatol 2007, 127:998-1008.
8. Lovvorn H.N., Cheung D.T., Nimni M.E., et al. Relative distribution and crosslinking of collagen distinguish fetal from adult sheep wound repair. J Pediatr Surg 1999, 34:218-223.
9. Freedberg I.M., Tomic-Canic M., Komine M., et al. Keratins and the keratinocyte activation cycle. J Invest Dermatol 2001, 116:633-640.
10. Hantash B.M., Zhao L., Knowles J.A., et al. Adult and fetal wound healing. Front Biosci 2008, 13:51-61.
11. Werner S., Grose R. Regulation of wound healing by growth factors and cytokines. Physiol Rev 2003, 83:835-870.
12. Barrientos S., Stojadinovic O., Golinko M.S., et al. Growth factors and cytokines in wound healing. Wound Repair Regen 2008, 16:585-601.
13. Bennett N.T., Schultz G.S. Growth factors and wound healing: Part II. Role in normal and chronic wound healing. Am J Surg 1993, 166:74-81.
14. Robson M.C., Hill D.P., Woodske M.E., et al. Wound healing trajectories as predictors of effectiveness of therapeutic agents. Arch Surg 2000, 135:773-777.
15. Nwomeh B.C., Yager D.R., Cohen I.K. Physiology of the chronic wound. Clin Plast Surg 1998, 25:341-356.
16. Mast B.A., Schultz G.S. Interactions of cytokines, growth factors, and proteases in acute and chronic wounds. Wound Repair Regen 1996, 4:411-420.
17. Tarnuzzer R.W., Schultz G.S. Biochemical analysis of acute and chronic wound environments. Wound Repair Regen 1996, 4:321-325.
18. Falanga V., Eaglstein W.H. The " trap" hypothesis of venous ulceration. Lancet 1993, 341:1006-1008.
19. Rumalla V.K., Borah G.L. Cytokines, growth factors, and plastic surgery. Plast Reconstr Surg 2001, 108:719-733.
20. Holman D.M., Kalaaji A.N. Cytokines in dermatology. J Drugs Dermatol 2006, 5:520-524.
21. Hu X., Sun H., Han C., et al. Topically applied rhGM-CSF for the wound healing: a systematic review. Burns 2011, 37:729-741.
22. Sauder D.N., Kilian P.L., McLane J.A., et al. Interleukin-1 enhances epidermal wound healing. Lymphokine Res 1990, 9:465-473.
23. Goretsky M.J., Harriger M.D., Supp A.P., et al. Expression of interleukin-1alpha, interleukin-6, and basic fibroblast growth factor by cultured skin substitutes before and after grafting to full-thickness wounds in athymic mice. J Trauma 1996, 40:894-899. [discussion: 899-900].
24. Finnerty C.C., Herndon D.N., Przkora R., et al. Cytokine expression profile over time in severely burned pediatric patients. Shock 2006, 26:13-19.
25. Chen J.D., Lapiere J.C., Sauder D.N., et al. Interleukin-1 alpha stimulates keratinocyte migration through an epidermal growth factor/transforming growth factor-alpha-independent pathway. J Invest Dermatol 1995, 104:729-733.
26. Gyulai R., Hunyadi J., Kenderessy-Szabo A., et al. Chemotaxis of freshly separated and cultured human keratinocytes. Clin Exp Dermatol 1994, 19:309-311.
27. Singer A.J., McClain S.A., Hacht G., et al. Semapimod reduces the depth of injury resulting in enhanced re-epithelialization of partial-thickness burns in swine. J Burn Care Res 2006, 27:40-49.
28. Robson M.C., Abdullah A., Burns B.F., et al. Safety and effect of topical recombinant human interleukin-1beta in the management of pressure sores. Wound Repair Regen 1994, 2:177-181.
29. Brauchle M., Angermeyer K., Hubner G., et al. Large induction of keratinocyte growth factor expression by serum growth factors and pro-inflammatory cytokines in cultured fibroblasts. Oncogene 1994, 9:3199-3204.
30. Streit M., Beleznay Z., Braathen L.R. Topical application of the tumour necrosis factor-alpha antibody infliximab improves healing of chronic wounds. Int Wound J 2006, 3:171-179.
31. Malik I.A., Zahid M., Haq S., et al. Effect of subcutaneous injection of granulocyte-macrophage colony stimulating factor (GM-CSF) on healing of chronic refractory wounds. Eur J Surg 1998, 164:737-744.
32. Jaschke E., Zabernigg A., Gattringer C. Recombinant human granulocyte-macrophage colony-stimulating factor applied locally in low doses enhances healing and prevents recurrence of chronic venous ulcers. Int J Dermatol 1999, 38:380-386.
33. Cruciani M., Lipsky B.A., Mengoli C., et al. Are granulocyte colony-stimulating factors beneficial in treating diabetic foot infections?: a meta-analysis. Diabetes Care 2005, 28:454-460.
34. Da Costa R.M., Ribeiro Jesus F.M., Aniceto C., et al. Randomized, double-blind, placebo-controlled, dose-ranging study of granulocyte-macrophage colony stimulating factor in patients with chronic venous leg ulcers. Wound Repair Regen 1999, 7:17-25.
35. Bennett N.T., Schultz G.S. Growth factors and wound healing: biochemical properties of growth factors and their receptors. Am J Surg 1993, 165:728-737.
36. Robson M.C. Growth factors as wound healing agents. Curr Opin Biotechnol 1991, 2:863-867.
37. Cohen S. Isolation of a mouse submaxillary gland protein accelerating incisor eruption and eyelid opening in the new-born animal. J Biol Chem 1962, 237:1555-1562.
38. Yarden Y. The EGFR family and its ligands in human cancer. Signalling mechanisms and therapeutic opportunities. Eur J Cancer 2001, 37(Suppl 4):S3-S8.
39. Cha D., O'Brien P., O'Toole E.A., et al. Enhanced modulation of keratinocyte motility by transforming growth factor-alpha (TGF-alpha) relative to epidermal growth factor (EGF). J Invest Dermatol 1996, 106:590-597.
40. McCawley L.J., O'Brien P., Hudson L.G. Epidermal growth factor (EGF)- and scatter factor/hepatocyte growth factor (SF/HGF)-mediated keratinocyte migration is coincident with induction of matrix metalloproteinase (MMP)-9. J Cell Physiol 1998, 176:255-265.
41. Martin P. Wound healing-aiming for perfect skin regeneration. Science 1997, 276:75-81.
42. Rheinwald J.G., Green H. Epidermal growth factor and the multiplication of cultured human epidermal keratinocytes. Nature 1977, 265:421-424.
43. Haase I., Evans R., Pofahl R., et al. Regulation of keratinocyte shape, migration and wound epithelialization by IGF-1- and EGF-dependent signalling pathways. J Cell Sci 2003, 116:3227-3238.
44. Luetteke N.C., Qiu T.H., Peiffer R.L., et al. TGF alpha deficiency results in hair follicle and eye abnormalities in targeted and waved-1 mice. Cell 1993, 73:263-278.
45. Mann G.B., Fowler K.J., Gabriel A., et al. Mice with a null mutation of the TGF alpha gene have abnormal skin architecture, wavy hair, and curly whiskers and often develop corneal inflammation. Cell 1993, 73:249-261.
46. Kim I., Mogford J.E., Chao J.D., et al. Wound epithelialization deficits in the transforming growth factor-alpha knockout mouse. Wound Repair Regen 2001, 9:386-390.
47. Brown G.L., Nanney L.B., Griffen J., et al. Enhancement of wound healing by topical treatment with epidermal growth factor. N Engl J Med 1989, 321:76-79.
48. Jameson J., Ugarte K., Chen N., et al. A role for skin gammadelta T cells in wound repair. Science 2002, 296:747-749.
49. auf demKeller U., Krampert M., Kumin A., et al. Keratinocyte growth factor: effects on keratinocytes and mechanisms of action. Eur J Cell Biol 2004, 83:607-612.
50. Steiling H., Werner S. Fibroblast growth factors: key players in epithelial morphogenesis, repair and cytoprotection. Curr Opin Biotechnol 2003, 14:533-537.
51. Igarashi M., Finch P.W., Aaronson S.A. Characterization of recombinant human fibroblast growth factor (FGF)-10 reveals functional similarities with keratinocyte growth factor (FGF-7). J Biol Chem 1998, 273:13230-13235.
52. Sanz Garcia S., Santos Heredero X., Izquierdo Hernandez A., et al. Experimental model for local application of growth factors in skin re-epithelialisation. Scand J Plast Reconstr Surg Hand Surg 2000, 34:199-206.
53. Hebda P.A., Klingbeil C.K., Abraham J.A., et al. Basic fibroblast growth factor stimulation of epidermal wound healing in pigs. J Invest Dermatol 1990, 95:626-631.
54. Marchese C., Chedid M., Dirsch O.R., et al. Modulation of keratinocyte growth factor and its receptor in reepithelializing human skin. J Exp Med 1995, 182:1369-1376.
55. Ortega S., Ittmann M., Tsang S.H., et al. Neuronal defects and delayed wound healing in mice lacking fibroblast growth factor 2. Proc Natl Acad Sci U S A 1998, 95:5672-5677.
56. Robson M.C., Phillips L.G., Lawrence W.T., et al. The safety and effect of topically applied recombinant basic fibroblast growth factor on the healing of chronic pressure sores. Ann Surg 1992, 216:401-406. [discussion: 406-8].
57. Robson M.C., Hill D.P., Smith P.D., et al. Sequential cytokine therapy for pressure ulcers: clinical and mechanistic response. Ann Surg 2000, 231:600-611.
58. Richard J.L., Parer-Richard C., Daures J.P., et al. Effect of topical basic fibroblast growth factor on the healing of chronic diabetic neuropathic ulcer of the foot. A pilot, randomized, double-blind, placebo-controlled study. Diabetes Care 1995, 18:64-69.
59. Shi Y., Massague J. Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 2003, 113:685-700.
60. Broughton G., Janis J.E., Attinger C.E. The basic science of wound healing. Plast Reconstr Surg 2006, 117:12S-34S.
61. Douglas H.E. TGF-β in wound healing: a review. J Wound Care 2010, 19:403-406.
62. Coffey R.J., Bascom C.C., Sipes N.J., et al. Selective inhibition of growth-related gene expression in murine keratinocytes by transforming growth factor beta. Mol Cell Biol 1988, 8:3088-3093.
63. Sellheyer K., Bickenbach J.R., Rothnagel J.A., et al. Inhibition of skin development by overexpression of transforming growth factor beta 1 in the epidermis of transgenic mice. Proc Natl Acad Sci U S A 1993, 90:5237-5241.
64. Yang L., Chan T., Demare J., et al. Healing of burn wounds in transgenic mice overexpressing transforming growth factor-beta 1 in the epidermis. Am J Pathol 2001, 159:2147-2157.
65. Ito Y., Sarkar P., Mi Q., et al. Overexpression of Smad2 reveals its concerted action with Smad4 in regulating TGF-beta-mediated epidermal homeostasis. Dev Biol 2001, 236:181-194.
66. Li A.G., Wang D., Feng X.H., et al. Latent TGFbeta1 overexpression in keratinocytes results in a severe psoriasis-like skin disorder. EMBO J 2004, 23:1770-1781.
67. Huang J.S., Wang Y.H., Ling T.Y., et al. Synthetic TGF-beta antagonist accelerates wound healing and reduces scarring. FASEB J 2002, 16:1269-1270.
68. Robson M.C., Phillip L.G., Cooper D.M., et al. Safety and effect of transforming growth factor-beta(2) for treatment of venous stasis ulcers. Wound Repair Regen 1995, 3:157-167.
69. Hirshberg J., Coleman J., Marchant B., et al. TGF-beta3 in the treatment of pressure ulcers: a preliminary report. Adv Skin Wound Care 2001, 14:91-95.
70. Cheng H., Jiang W., Phillips F.M., et al. Osteogenic activity of the fourteen types of human bone morphogenetic proteins (BMPs). J Bone Joint Surg Am 2003, 85:1544-1552.
71. Burkus J.K., Transfeldt E.E., Kitchel S.H., et al. Clinical and radiographic outcomes of anterior lumbar interbody fusion using recombinant human bone morphogenetic protein-2. Spine (Phila Pa 1976) 2002, 27:2396-2408.
72. Govender S., Csimma C., Genant H.K., et al. Recombinant human bone morphogenetic protein-2 for treatment of open tibial fractures: a prospective, controlled, randomized study of four hundred and fifty patients. J Bone Joint Surg Am 2002, 84:2123-2134.
73. Niessen F.B., Andriessen M.P., Schalkwijk J., et al. Keratinocyte-derived growth factors play a role in the formation of hypertrophic scars. J Pathol 2001, 194:207-216.
74. Uutela M., Wirzenius M., Paavonen K., et al. PDGF-D induces macrophage recruitment, increased interstitial pressure, and blood vessel maturation during angiogenesis. Blood 2004, 104:3198-3204.
75. Bennett S.P., Griffiths G.D., Schor A.M., et al. Growth factors in the treatment of diabetic foot ulcers. Br J Surg 2003, 90:133-146.
76. Vogt P.M., Lehnhardt M., Wagner D., et al. Determination of endogenous growth factors in human wound fluid: temporal presence and profiles of secretion. Plast Reconstr Surg 1998, 102:117-123.
77. Trengove N.J., Bielefeldt-Ohmann H., Stacey M.C. Mitogenic activity and cytokine levels in non-healing and healing chronic leg ulcers. Wound Repair Regen 2000, 8:13-25.
78. Steed D.L. Clinical evaluation of recombinant human platelet-derived growth factor for the treatment of lower extremity diabetic ulcers. Diabetic Ulcer Study Group. J Vasc Surg 1995, 21:71-78. [discussion: 79-81].
79. Nissen N.N., Polverini P.J., Koch A.E., et al. Vascular endothelial growth factor mediates angiogenic activity during the proliferative phase of wound healing. Am J Pathol 1998, 152:1445-1452.
80. Gaudry M., Bregerie O., Andrieu V., et al. Intracellular pool of vascular endothelial growth factor in human neutrophils. Blood 1997, 90:4153-4161.
81. Pepper M.S., Ferrara N., Orci L., et al. Potent synergism between vascular endothelial growth factor and basic fibroblast growth factor in the induction of angiogenesis in vitro. Biochem Biophys Res Commun 1992, 189:824-831.
82. Galiano R.D., Tepper O.M., Pelo C.R., et al. Topical vascular endothelial growth factor accelerates diabetic wound healing through increased angiogenesis and by mobilizing and recruiting bone marrow-derived cells. Am J Pathol 2004, 164:1935-1947.
83. Geva R., Prenen H., Topal B., et al. Biologic modulation of chemotherapy in patients with hepatic colorectal metastases: the role of anti-VEGF and anti-EGFR antibodies. J Surg Oncol 2010, 102:937-945.
84. Pierce G.F., Tarpley J.E., Tseng J., et al. Detection of platelet-derived growth factor (PDGF)-AA in actively healing human wounds treated with recombinant PDGF-BB and absence of PDGF in chronic nonhealing wounds. J Clin Invest 1995, 96:1336-1350.
85. Robson M.C., Mustoe T.A., Hunt T.K. The future of recombinant growth factors in wound healing. Am J Surg 1998, 176:80S-82S.
86. Bevan S., Martin R., McKay I.A. The production and applications of genetically modified skin cells. Biotechnol Genet Eng Rev 1999, 16:231-256.
87. Jang J.H., Houchin T.L., Shea L.D. Gene delivery from polymer scaffolds for tissue engineering. Expert Rev Med Devices 2004, 1:127-138.
88. Liechty K.W., Nesbit M., Herlyn M., et al. Adenoviral-mediated overexpression of platelet-derived growth factor-B corrects ischemic impaired wound healing. J Invest Dermatol 1999, 113:375-383.
89. Margolis D.J., Crombleholme T., Herlyn M. Clinical protocol: phase I trial to evaluate the safety of H5.020CMV.PDGF-B for the treatment of a diabetic insensate foot ulcer. Wound Repair Regen 2000, 8:480-493.
90. Brem H., Kodra A., Golinko M.S., et al. Mechanism of sustained release of vascular endothelial growth factor in accelerating experimental diabetic healing. J Invest Dermatol 2009, 129:2275-2287.
91. Saaristo A., Tammela T., Farkkila A., et al. Vascular endothelial growth factor-C accelerates diabetic wound healing. Am J Pathol 2006, 169:1080-1087.
92. Ailawadi M., Lee J.M., Lee S., et al. Adenovirus vector-mediated transfer of the vascular endothelial growth factor cDNA to healing abdominal fascia enhances vascularity and bursting strength in mice with normal and impaired wound healing. Surgery 2002, 131:219-227.
93. Romano Di Peppe S., Mangoni A., Zambruno G., et al. Adenovirus-mediated VEGF(165) gene transfer enhances wound healing by promoting angiogenesis in CD1 diabetic mice. Gene Ther 2002, 9:1271-1277.
94. Lee B., Vouthounis C., Stojadinovic O., et al. From an enhanceosome to a repressosome: molecular antagonism between glucocorticoids and EGF leads to inhibition of wound healing. J Mol Biol 2005, 345:1083-1097.
95. Escamez M.J., Carretero M., Garcia M., et al. Assessment of optimal virus-mediated growth factor gene delivery for human cutaneous wound healing enhancement. J Invest Dermatol 2008, 128:1565-1575.
96. Cianfarani F., Tommasi R., Failla C.M., et al. Granulocyte/macrophage colony-stimulating factor treatment of human chronic ulcers promotes angiogenesis associated with de novo vascular endothelial growth factor transcription in the ulcer bed. Br J Dermatol 2006, 154:34-41.
97. Lu L., Saulis A.S., Liu W.R., et al. The temporal effects of anti-TGF-beta1, 2, and 3 monoclonal antibody on wound healing and hypertrophic scar formation. J Am Coll Surg 2005, 201:391-397.
98. Geusens B., Sanders N., Prow T., et al. Cutaneous short-interfering RNA therapy. Expert Opin Drug Deliv 2009, 6:1333-1349.
99. Lu P.Y., Xie F., Woodle M.C. In vivo application of RNA interference: from functional genomics to therapeutics. Adv Genet 2005, 54:117-142.